Clinical value of Positron Emission Tomography (PET) in oncology: Results of an interdisciplinary consensus conference;KLINISCHE WERTIGKEIT DER POSITRONEN-EMISSIONS-TOMOGRAPHIE (PET) BEI ONKOLOGISCHEN FRAGESTELLUNGEN: ERGEBNISSE EINER INTERDISZIPLINAREN KONSENSUSKONFERENZ

NuklearMedizin

Volumn 35, Issue 2, 1996, Pages 42-52

  Reske, S N ^a   Bares, R ^b   Bull U ^c   Guhlmann, A ^a   Moser, E ^d   Wannenmacher, M F ^e  

^a UNIVERSITY HOSPITAL ULM   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c RWTH AACHEN UNIVERSITY   (Germany)

^d UNIVERSITY OF FREIBURG   (Germany)

^e UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

FDG; oncology; PET

Indexed keywords

FLUORINE 18; FLUOROTYROSINE; METHIONINE C 11; UNCLASSIFIED DRUG;

CANCER; CANCER STAGING; CONFERENCE PAPER; CONTROLLED STUDY; DIAGNOSTIC VALUE; HUMAN; POSITRON EMISSION TOMOGRAPHY;

EID: 0029939382     PISSN: 00295566     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1629694     Document Type: Conference Paper

References (98)

1. Shields AF, Lim K, Grierson J, Link J, Krohn KA. Utilization of labeled thymidine in DNA synthesis; studies for PET. J Nucl Med 1990; 31: 337-42.
2. Fujiwara T, Matsuzawa T, Kubota K, Abe Y, Itoh M, Fukuda H, Hatazawa J, Yoshioka S, Yamaguchi K, Ito K. Relationship between histologic type of primary lung cancer and carbon-11-L-methionine uptake with positron emission tomography. J Nucl Med 1989; 30: 33-7.
3. Coenen HH, Kling P, Stocklin G, Cerebral metabolism of L-[2-18F]fluorotyrosine, a new PET tracer of protein synthesis. J Nucl Med 1989; 30: 1367-72.
4. Finkelstein JD, Martin JJ. Methionine metabolism in mammals. J Biol Chem 1986; 261: 1582-7.
5. Warburg O. The metabolism of tumors Richard R. Smith Inc., New York 1931, pp 129-69.
6. Hiraki Y, Rosen OM, Birnbaum MJ. Growth factors rapidly induce expression of the glucose transporter gene. J Biol Chem 1988: 263: 13655-62.
7. Som P, Atkins HI, Bandophadhyah D, Fowler JS, MacGregor RR, Matsui K, et al. A fluorinated glucose analog, 2-fluoro-2-deoxy-D-glucose (F-18): nontoxic tracer for rapid tumor detection. J Nucl Med 1980; 21: 670-5.
8. Strauss LG, Conti PS. The applications of PET in clinical oncology. J Nucl Med 1991; 32: 623-48.
9. 18F]fluoro-2-deoxy-D-glucose. J Comput Assist Tomogr 1993; 17: 582-9.
10. Mintun MA, Welch MJ, Siegel BA, Mathias CJ, Brodack JW, McGuire AH, Katzenellenbogen JA. Breast cancer: PET imaging of estrogen receptors. Radiology 1988; 169: 45-8.
11. 18F]fluoTO-17β-estradiol uptake in metastatic breast carcinoma. J Nucl Med 1991; 32: 1526-31.
12. Dehdashti F, Mortimer JE, Siegel BA, Griffeth LK, Bonasera TJ, Fusselman MJ, et al. Positron tomographic assessment of estrogen receptors in breast cancer: comparison with FDG-PET and in vitro receptor assays. J Nucl Med 1995, 36: 1766-74.
13. Shulkin BL, Wieland DM, Schwaiger M, Thompson NW, Francis IR, Haka MS. et al. PET scanning with hydroxyephedrine: an approach to the localization of pheochromocytoma. J Nucl Med 1992; 33: 1125-31.
14. Vaidyanathan G, Affleck DJ, Zalutsky MR. Validation of 4-[Fluorine-18]Fluoro-3-Iodobenzylguanidine as a Positron-Emitting Analog of MIBG. J Nucl Med 1995: 36: 644-50.
15. Westera G, Reist HW, Buchegger F, et al. Radioimmuno positron emission tomography with monoclonal antibodies: a new approach to quantifying in vivo tumor concentration and biodistribution for radioimmunotherapy. Nucl Med Commun 1991; 12: 429.
16. 121I in patients with breast cancer. Int J Cancer 1991; 47, 344-7.
17. Anderson CJ, Connett JM, Schwarz SW, et al. Copper-64-labeled antibodies for PET imaging. J Nucl Med 1992; 33: 1685-91.
18. Philpott GW, Schwarz SW, Anderson CJ, Dehdashti F, Connett JM, Zinn KR, Meares CF. et al. RadioimmunoPET: detection of colorectal carcinoma with positron-emitting copper-64-labeled monoclonal antibody. J Nucl Med 1995; 36: 1818-24.
19. 18F]Fluorodeoxyglucose Method for the Measurement of Local Cerebral Glucose Utilization in Man. Circ Res 1979; 44: 127-37.
20. 82Rb positron emission tomography. J Comput Assist Tomogr 1987; 11: 563-70.
21. DiChiro G, Oldfield E, Wright DC, DeMichele D. Katz DA, Patronas NJ, Doppman JL, et al. Cerebral necrosis after radiotherapy and/or intraarterial chemotherapy for brain tumors: PET and neuropathologic studies. AJR 1988; 150: 189-97.
22. Ogawa T, Kanno I, Shishido F, et al. Clinical value of PET with F-18-fluorodeoxyglucose and 1-methyl-C-11-methionine for diagnosis of recurrent brain tumor and radiation injury. Acta Radiol 1991; 32: 197-202.
23. 18F-fluorodeoxyglucose PET. AJR 1994; 163: 1459-65.
24. Patz EF, Lowe VJ, Hoffman JM, Paine SS, Harris LK, Goodman PC. Persistent or recurrent bronchogenic carcinoma: detection with PET and 2-[F-18]-2-deoxy-D-glucose. Radiology 1994; 191: 379-82.
25. Inoue T, Kim EE, Komaki R, Wong FCL, Bassa P, Wong WH, et al. Detecting recurrent or residual lung cancer with FDG-PET. J Nucl Med 1995; 36: 788-93.
26. Frank A, Lefkowitz D, Jaeger S, Gobar L, Sunderland J, Gupta N, et al. Decision logic for retreatment of asymptomatic lung cancer recurrence based on positron emission tomography findings. Int J Radiat Oncol Biol Phys 1995; 32: 1495-1512.
27. Strauss LG, Clorius JH, Schlag P, Lehner B, Kimmig B, Engenhart R. et al. Recurrence of colorectal tumors: PET evaluation. Radiology 1989; 170: 329-32.
28. Ito K, Kalo T, Tadokoro M, Ishiguchi T, Oshima M, Ishigaki T, Sakuma S. Recurrent rectal cancer and scar: differentiation with PET and MR imaging. Radiology 1992; 182. 549-52.
29. Wahl RL, Quint LE, Greenough RL, Meyer CR, White RI, Orringer MB. Staging of mediastinal non-small cell lung cancer with FDG PET, CT, and fusion images: preliminary prospective evaluation. Radiology 1994; 191: 371-7.
30. 18F] fluorodeoxyglucose. Ann Thorac Surg 1994; 58: 698-703.
31. Braams JW, Pruim J, Freling NJM, Nikkels PGJ, Roodenburg JLN, Boering G. et al. Detection of lymph node metastases of squamous-cell cancer of the head and neck with FDG-PET and MRI. J Nucl Med 1995; 36: 211-6.
32. Laubenbacher C, Saumweber D, Wagner-Manslau C, Kau RJ, Herz M, Avril N, et al. Comparison of fluorine-18- fluorodeoxyglucose PET, MRI and endoscopy for staging head and neck squamous-cell carcinomas. J Nucl Med 1995; 36: 1747-57.
33. Newman JS, Francis IR, Kaminski MS, Wahl RL. Imaging of lymphoma with PET with 2-[F-18]-fluoro-2-deoxy-D-glucose: correlation with CT. Radiology 1994; 190: 111-6.
34. Adler LP, Crowe JP, Al-Kaisi NK, Sunshine JL. Evaluation of breast masses and axillary lymph nodes with [F-18]2-deoxy-2-fluoro-D-glucose PET. Radiology 1993; 187: 743-50.
35. Stollfuß J, Glutting G, Friess H, Kocher F, Beger HG, Reske SN. 2-(Fluorine-18)-fluoro-2-deoxy-D-glucose PET in detection of pancreatic cancer: value of quantitative image interpretation. Radiology 1995; 195: 339-44.
36. Bares R, Klever P, Hauptmann S, Hellwig D, Fass J, Cremerius U, et al. F-18 Fluorodeoxyglucose PET in vivo evaluation of pancreatic glucose metabolism for detection of pancreatic cancer. Radiology 1994; 192: 79-86.
37. Inokuma T, Tamaki N, Torizuka T, Magata Y, Fujii M, Yonekura Y, et al. Evaluation of pancreatic tumors with positron emission tomography and F-18 fluorodeoxyglucose: comparison with CT and US. Radiology 1995; 195: 345-52.
38. Nolop KB, Rhodes CG, Brudin LH, Beaney RP, Krausz T, Jones T, et al. Glucose utilization in vivo by human pulmonary neoplasms. Cancer 1987; 60: 2682-9.
39. Kubota K, Matsuzawa T, Fujiwara T, Ito M, Hatazawa J, Ishiwata K, et al. Differential diagnosis of lung tumor. J Nucl Med 1990; 31: 1927-33.
40. Gupta NC, Frank AR, Dewan NA, Redepenning LS, Rothberg ML, Mailliard JA, et al. Solitary pulmonary nodules: detection of malignancy with PET with 2-[F-18]-fluoro-2-deoxy-D-glucose. Radiology 1992; 184: 441-4.
41. Patz EF, Lowe VJ, Hoffman JM, Paine SS, Burrowes P, Coleman RE, et al. Focal pulmonary abnormalities: evaluation with F-18 fluorodeoxyglucose PET scanning. Radiology 1993; 188: 487-90.
42. Rege SD, Hoh CK, Glaspy JA, Aberle DR, Dahlborn M, Razavi MK, et al. Imaging of pulmonary mass lesions with whole-body positron emission tomography and fluorodeoxyglucose. Cancer 1993; 72: 82-90.
43. Dcwan NA, Gupta NC, Redepenning LS, Phalen JJ, Frick MP. Diagnostic efficacy of PET-FDG imaging in solitary pulmonary nodules. Potential role in evaluation and management. CHEST 1993; 104: 997-1002.
44. Lowe VJ, Hoffman JM, DeLong DM, Patz EF, Coleman RE. Semiquantitative and visual analysis of FDG-PET images in pulmonary abnormalities. J Nucl Med 1994; 35: 1771-6.
45. 18F-fluorodeoxyglucose positron emission tomography in preoperative evaluation of lung cancer. Lancet 1994; 344: 1265-6.
46. Storck M, Grimmel S, Henrich MM, Liewald F, Reske SN, Sunder-Plassmann L. Diagnostische Wertigkeit der Positronen-Emissions-Tomographie mit Fluor-Deoxy-Glucose (18-FDG) bei Patienten mit Bronchialkarzinom. Z Herz-. Thorax-, Gefäßchir 1994; 8: 126-30.
47. ACC/AHA Task Force Report. Guidelines for Clinical Use of Cardiac Radionuclide Imaging. Report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Committee on Radionuclide Imaging), Developed in Collaboration With the American Society of Nuclear Cardiology. JACC 1995; 25 (2): 521-7.
48. 18F)fluorotyrosine. J Nucl Med 1991; 32: 1338-46.
49. Lilja A, Lundqvist H, Olsson Y, Spånnare B, Gullberg P, Långström B. Positron emission tomography and computed tomography in differential diagnosis between recurrent or residual glioma and treatment-induced brain lesions. Acta Radid 1989; 30: 121-8.
50. 18F] fluorodeoxyglucose positron emission tomography. Ann Neurol 1991; 29: 347-55.
51. Valk PE, Budinger TF, Levin VA, Silver P, Gutin PH, Doyle WK. PET of malignant cerebral tumors after interstitial brachytherapy. Demonstration of metabolic activity and correlation with clinical outcome. J Neurosurg 1988; 69: 830-8.
52. Franca villa TL, Miletech RS, Di Chiro G, Patronas NJ, Rizzli HV, Wright DC. Positron emission tomography in the detection of malignant degeneration of low-grade-gliomas. Neurosurgery 1989; 24: 1-5.
53. Rege S, Maass A, Chaiken L, Hoh CK, Choi Y, Lufkin R, et al. Use of positron emission tomography with fluorodeoxyglucose in patients with extracranial head and neck cancers. Cancer 1994: 73: 3047-58.
54. Mancuso AA, Drane WE, Mukherji SK. The promise FDG in diagnosis and surveillance of head and neck cancer [Editorial]. Cancer 1994; 74: 1193-5.
55. Haberkorn U, Strauss LG, Dimitrakopoulou A, Engenhart R, Oberdorfer F, Ostertag H, et al. PET studies of fluorodeoxyglucose metabolism in patients with recurrent colorectal tumors receiving radiotherapy J Nucl Med 1991; 32: 1485-90.
56. Bangerter M, Kocher F, Binder T, Griesshammer M, Heimpel H, Sandherr M, Reske SN. Total body positron emission tomography (PET) for staging and follow-up of lymphoma. Proc ASCO 1995, 14: 387 (Abstract).
57. Harms W, Bares R, Kamps H, Gronimus R, Boeckmann W, Jakse G, Bull U. Therapy control of metastatic testicular carcinoma with F-18-DOG PET. J Nucl Med 1995; 36: 198P (Abstr).
58. Steinert H, Huch-Böni RA, Buck A, Böni R, Berthold T, Marincek B, et al. Malignant melanoma: staging with wholebody position emission tomography and 2-[F-18]-fluoro-2-deoxy-D-glucose. Radiology 1995; 195: 705-9.
59. Glitters LS, Francis IR, Zasadny KR, Wahl RL. Initial assessment of positron emission tomography using 2-fluorine-18-fluoro-2-deoxy-D-glucose in the imaging of malignant melanoma. J Nucl Med 1993; 34: 1420-7.
60. 131J. Nucl.-Med. 1995; 34: 127-34.
61. Sisson JC, Ackermann RJ, Meyer MA, Wahl RL. Uptake of 18-fluoro-2-dcoxy-D-glucose by thyroid cancer: implications for diagnosis and therapy. J clin Endocrin Metabol 1993; 77: 1090-4.
62. Joensuu H, Ahonen A. Imaging of metastases of thyroid carcinoma with fluorine-18 fluorodeoxyglucose. J Nucl Med 1987; 28: 910-4.
63. Bachor R, Kocher F, Gropengießer F, Reske SN, Hautmann RE. Positronenemissionstomographie. Einführung eines neuen Verfahrens in die Diagnostik urologischer Tumoren und erste klinische Ergebnisse. Urologe [A] 1995; 34: 138-42.
64. Müller-Mattheis V, Reinhardt M, Müller-Gärtner HW, Ackermann R. Erfassung von Lymphknotenmetastasen urologischer Malignome durch die Positron-Emissions-Tomographic (PET) mit Fluordeoxyglukose (18F-FDG). Urologe [A] 1994; 33: 29.
65. Pierce MA, Johnson MD, Maciunas RJ, Murray MJ, Allen GS, Harbison MA, Creasy JL, Kessler RM. Evaluating Contrast-Enhancing Brain Lesions in Patients with AIDS by Using Positron Emission Tomography. Ann Intern Med 1995; 123: 594-8.
66. Greven KM, Williams DW, Keyes JW, McGuirt WF, Watson NE, Randall ME, et al. Positron emission tomography of patients with head and neck carcinoma before and after high dose irradiation. Cancer 1994; 74. 1355-9.
67. Dimitrakopoulou A, Strauss LG, Clorius JH, Ostertag H, Schlag P, Heim M, et al. Studies with positron emission tomography after systemic administration of fluorine-18-uracil in patients with liver metastases from colorectal carcinoma. J Nucl Med 1993; 34: 1075-81.
68. Okazumi S, Isono K, Enomoto K, Kikuchi T, Ozaki M,Yamamoto H, Hayashi H, Asano T, Ryu M. Evaluation of liver tumors using fluorine-18-fluorodeoxyglucose PET: characterization of tumor and assessment of effect of treatment. J Nucl Med 1992; 33. 333-9.
69. Okada J, Yoshikawa K, Imazeki K, Minoshima S, Uno K, Itami J, et al. The use of FDG-PET in the detection and management of malignant lymphoma: correlation of uptake with prognosis. J Nucl Med 1991; 32: 686-91.
70. Hoekstra OS, Ossenkoppele GJ, Golding R, van Lingen A, Visser GWM, Teule GJJ, et al. Early treatment response in malignant lymphoma, as determined by planar fluorine-18-fluorodeoxyglucose scintigraphy. J Nucl Med 1993; 34: 1706-10.
71. Wahl, RL, Cody RL, Hutchins GD, Mudgett EE. Primary and metastatic breast carcinoma: initial clinical evaluation with PET with the radiolabeled glucose analogue 2-[F-18]-fluoro-2-deoxy-D-glucose. Radiology 1991; 179: 765-70.
72. Nieweg OE, Kim EE, Wong WH, Broussard WF, Singletary SE. et al. Positron emission tomography with fluorine-18-deoxyglucose in the detection and staging of breast cancer. Cancer 1993; 71: 3920-5.
73. Tse NY, Hoh CK, Hawkins RA, Zinner MJ, Dahlbom M, Choi Y, et al. The application of positron emission tomographic imaging with fluorodeoxyglucose to the evaluation of breast disease. Ann Surg 1992; 216: 27-34.
74. Avril N, Jänicke F, Dose J, Bense S, Ziegler S. Zinke M, Laubenbacher C,Römer W, Herz M, Schwaiger M. PET imaging of breast tumor: Munich Experience. J Nucl Med 1995; 36: 82P (Abstr).
75. Huovinen R, Leskinen-Kailio S, Någren K, Lehikomen P, Ruotsalainen U, Teräs M. Carbon-11-methionine and PET in evaluation of treatment response of breast cancer Br J Cancer 1993; 67: 787-91.
76. Wahl RL, Zasadny K, Helvie M, Hutchins GD, Weber B, Cody R. Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation. J Clin Oncol 1993; 11: 2101-11.
77. 18F]Fluorodeoxyglucose scintigraphy in diagnosis and follow up of treatment in advanced breast cancer. Eur J Nucl Med 1989; 15: 61-6.
78. Casey MJ, Gupta NC, Muths CK. Experience with positron emission tomography (PET) scans in patients with ovarian cancer. Gynecol Oncol 1994; 53: 331-8.
79. 18F]-fluoro-2-deoxy-D-glucose can detect recurrent ovarian carcinoma. Gynecol Oncol 1993; 51: 175-81.
80. Di Chiro G, Hatazawa J, Katz DA, Rizzoli HV, DeMichele DJ. Glucose utilization by intracranial meningiomas as an index of tumor aggressivity and probability of recurrence: a PET study. Radiology 1987; 164: 521-6.
81. Alavi JB, Alavi A, Chawluk J, Kushner M, Powe J, Hickey W, Rcivich M. Positron emission tomography in patients with glioma. A predictor of prognosis. Cancer 1988; 62: 1074-8.
82. Holthoff VA, Herholz K, Berthold F, Widemann B, Schröder R, Neubauer I, Heiss WD. In vivo metabolism of childhood posterior fossa tumors and primitive neuroectodermal tumors before and after treatment. Cancer 1993; 72: 1394-1403.
83. Hölzer T, Herholz K, Jeske J, Heiss WD. FDG-PET as a prognostic indicator in radiochemotherapy of glioblastoma. J Comput Assist Tomogr 1993; 17: 681-7.
84. De Witte O, Hildebrand J, Luxen A, Goldman S. Acute effect of carmustine on glucose metabolism in brain and glioblastoma. Cancer 1994; 74: 2836-42.
85. Haberkorn U, Strauss LG, Dimitrakopoulou A, Seiffert E, Oberdorfer F, Zicgler S, et al. Fluorodeoxyglucose imaging of advanced head and neck cancer after chemotherapy. J Nucl Med 1993; 34: 12-7.
86. Minn H, Paul R, Ahonen A. Evaluation of treatment response to radiotherapy in head and neck cancer with fluorine-18 fluorodeoxyglucose J Nucl Med 1988; 29: 1521-5.
87. Ichiya Y, Kuwabara Y, Otsuka M, Tahara T, Yoshikai T, Fukumura T, et al. Assessment of response to cancer therapy using fluorine-18-fluorodeoxyglucose and positron emission tomography. J Nucl Med 1991; 32: 1655-60.
88. 11C]methionine: a preliminary study. Eur J Nucl Med 1993; 20: 495-501.
89. 18F-2-fluoro-2-deoxy-D-glucose and positron emission tomography: preliminary study of lung cancer. Int J Radiol Oncol Biol Phys 1990; 19. 1005-10.
90. Torizuka T, Tamaki N, Inokuma T, et al. Value of fluorine-18-FDG-PET to monitor hepatocellular carcinoma after interventional therapy. J Nucl Med 1994; 35: 1965-9.
91. 18F]FDG positron emission tomography. J Comput Assist Tomogr 1990; 14: 370-4.
92. Goldberg MA, Lee MJ, Fischman AJ, Mueller PR, Alpert NM, Thrall JH. Fluorodeoxyglucose PET of abdominal and pelvic neoplasms: potential role in oncologic imaging. RadioGraphics 1993; 13: 1047-62.
93. 18F]fluorodeoxyglucose in recurrent colorectal cancer. Br J Surg 1994; 81: 1666-70.
94. Engenhart R, Kimmig B, Höver KH, Strauss LG, Lorenz WJ. Wannenmacher M. Photon-neutron therapy for recurrent colorectal cancer - follow up and preliminary results. Strahlenther Onkol 1990; 166: 95-8.
95. Engenhart R, Kimmig BN, Strauß LG, Höver KH, Romahn J, Haberkorn U, van Kaick G, Wannenmacher M. Therapy monitoring of presacral recurrences after high-dose irradiation: value of PET, CT, CEA and pain score. Strahlenther Onkol 1992; 168: 203-12.
96. Reinhardt M, Müller-Mattheis V, Vosberg H, Ackermann R, Müller-Gärtner HW. Sta-ging of lymph nodes in testicular cancer by FDG-PET. Eur J Nucl Med 1995; 22: 804.
97. Effert PJ, Bares R, Handt S, Wolff JM, Büll U, Jakse Gerhard. Metabolic imaging of untreated prostate cancer by positron emission tomography with fluorine-18-labeled deoxyglucose (FDG-PET). Urology 1996, im Druck.
98. Hübner KF. Clinical Applications of PET in Ovarian Cancer. An Alternative To Second-Look-Surgcry. Institute for Clinical PET. Seventh Annual International PET Conference, San Francisco 1995.